ST. LOUIS--(BUSINESS WIRE)--Euclises Pharmaceuticals, Inc., a biotechnology company developing novel COX-2 inhibitors for the treatment of cancer, today announced closing a $1.3 million Series A financing. Founded by John Talley, one of the pioneers of selective cyclooxygenase-2 (“COX-2”) inhibitors, Euclises will use proceeds from the financing to prepare its Euclicoxib® product candidates for clinical trials in cancer patients.
Euclises’ Series A financing was led by Cultivation Capital, a St. Louis-based early-stage venture capital firm, and included participation by BioGenerator, Missouri Technology Corporation, ABC Laboratories, the St. Louis County Port Authority’s Helix Fund and the St. Louis Arch Angels.
Help employers find you! Check out all the jobs and post your resume.
